Integral Health Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Integral Health Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-130,000	Closed	-$1.93M	–	66
2022 Q3	$1.93M	Sell	130,000 -26,553	-17%	-$446K	0.37%	59
2022 Q2	$2.46M	Buy	156,553 +31,553	+25%	+$619K	0.51%	54
2022 Q1	$3.37M	Buy	125,000 +60,000	+92%	+$1.53M	0.88%	40
2021 Q4	$2.41M	Sell	65,000 -20,000	-24%	-$815K	0.67%	47
2021 Q3	$4.06M	Buy	+85,000	New	+$3.81M	1.17%	33

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Integral Health Asset Management's ARCT Position: Q4 2022 in Review

Integral Health Asset Management sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 130,000 shares — an estimated $1.93M sold.

Integral Health Asset Management first reported a position in ARCT in Q3 2021 and held it in 5 quarters. The position peaked at $4.06M in Q3 2021. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

Integral Health Asset Management reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
Integral Health Asset Management sold 130,000 Arcturus Therapeutics shares in Q4 2022, an estimated $1.93M.
Integral Health Asset Management first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 5 quarters.
Integral Health Asset Management's Arcturus Therapeutics position peaked at $4.06M in Q3 2021.
111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on Integral Health Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.